Open Access

A meta‑analysis of serological thymidine kinase 1 as a marker for colorectal benign and malignant tumor risk assessment

  • Authors:
    • Li Dang
    • Hongbo Ma
    • Ailian Hei
    • Shuai Xu
    • Ji Zhou
    • Ellen He
    • Sven Skog
  • View Affiliations

  • Published online on: February 25, 2020     https://doi.org/10.3892/mco.2020.2002
  • Pages: 440-450
  • Copyright: © Dang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study investigated whether a concentration of serum thymidine kinase 1 (STK1p) could be used to distinguish between healthy individuals, patients with colorectal benign tumors and individuals with colorectal cancer (CRC). The effectiveness of surgery on patients with CRC was monitored. A total of 20 publications containing patients with CRC (n=1,836), patients with colorectal benign tumors (n=774) and healthy controls (n=1,701) were analysed in the present meta‑analysis. The publications were collected from PubMed, Embase, CENTRAL, CNKI, Wanfang, VIP and SinoMed databases from January 1, 2009 until August 31, 2019. Articles were analyzed according to sensitivity (Forest plot) and publication bias (Begg's plot, Egger's linear regression) using fixed or random effect models to calculate the weighted mean difference. Study quality was checked using the Newcastle‑Ottawa Scale Document Quality Assessment Scale. The meta‑analysis followed the PRISMA statement. The results revealed that STK1p significantly distinguished healthy individuals and those with colorectal benign tumors from patients with CRC, and from patients with benign tumors (P<0.000001). STK1p levels also decreased by 40% following surgery (P<0.0001), which corresponded to half‑life of ~1 month. The quality of the present study was high and no bias was identified among publication. It was concluded that STK1p was a reliable biomarker for the early detection of benign lesions, which may therefore prevent their future development into colorectal malignancies. STK1p may also be used for the clinical dynamic monitoring of the effectiveness of surgery in patients with CRC. Combining STK1p with colorectal‑associated biomarkers, in addition to the determination of tumor stage and grade may therefore be of use.
View Figures
View References

Related Articles

Journal Cover

May 2020
Volume 12 Issue 5

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Dang, L., Ma, H., Hei, A., Xu, S., Zhou, J., He, E., & Skog, S. (2020). A meta‑analysis of serological thymidine kinase 1 as a marker for colorectal benign and malignant tumor risk assessment. Molecular and Clinical Oncology, 12, 440-450. https://doi.org/10.3892/mco.2020.2002
MLA
Dang, L., Ma, H., Hei, A., Xu, S., Zhou, J., He, E., Skog, S."A meta‑analysis of serological thymidine kinase 1 as a marker for colorectal benign and malignant tumor risk assessment". Molecular and Clinical Oncology 12.5 (2020): 440-450.
Chicago
Dang, L., Ma, H., Hei, A., Xu, S., Zhou, J., He, E., Skog, S."A meta‑analysis of serological thymidine kinase 1 as a marker for colorectal benign and malignant tumor risk assessment". Molecular and Clinical Oncology 12, no. 5 (2020): 440-450. https://doi.org/10.3892/mco.2020.2002